COMMUNICATION
Attenuation of Interleukin 2 Signal in the Spleen Cells of Complex Ganglioside-lacking Mice*

Jinmin ZhaoDagger , Keiko Furukawa§, Satoshi Fukumoto§, Masahiko Okadaparallel , Reiko Furugen**, Hiroshi Miyazaki§, Kogo TakamiyaDagger Dagger Dagger §§, Shinichi AizawaDagger Dagger , Hiroshi Shiku¶¶, Toshifumi MatsuyamaDagger , and Koichi Furukawa§||

From the Departments of Dagger  Oncology and parallel  Pediatrics, Nagasaki University School of Medicine and the Departments of  Pediatric Dentistry and ** Preventive Dentistry, Nagasaki University School of Dentistry, Sakamoto, Nagasaki, 852-8102, the § Department of Biochemistry II, Nagoya University School of Medicine, Tsurumai, Nagoya, 466-0065, Dagger Dagger  Laboratory of Morphogenesis, Institute of Molecular Embryology and Genetics, Kumamoto University School of Medicine, Honsho, Kumamoto, 860-0811, and the ¶¶ Department of Internal Medicine, Mie University School of Medicine, Tsu, Mie, 514-0001 Japan

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

T cell development and function in complex ganglioside-lacking (GM2/GD2 synthase gene-disrupted) mice were analyzed. GM1, asialo-GM1, and GD1b were representative gangliosides expressed on T cells of the wild type mice and completely deleted on those of the mutant mice. The sizes and cell numbers of the mutant mice spleen and thymus were significantly reduced. Spleen cells from the mutant mice showed clearly reduced proliferation compared with the wild type when stimulated by interleukin 2 (IL-2) but not when treated with concanavalin A or anti-CD3 cross-linking. Expression levels of IL-2 receptor alpha , beta , and gamma  were almost equivalent, and up-regulation of alpha  chain after T cell activation was also similar between the mutant and wild type mice. Activation of JAK1, JAK3, and SAT5 after IL-2 treatment was reduced, and c-fos expression was delayed and reduced in the mutant spleen cells, suggesting that the IL-2 signal was attenuated in the mutant mice probably due to the modulation of IL-2 receptors by the lack of complex gangliosides.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Gangliosides are enriched in nervous systems of vertebrates, suggesting their importance in the neuronal functions (1). They are also present in cells of the immune system and have been thought to contribute in cell to cell recognition or cellular signal modulation (2). In particular in human T cells, GD31 was induced by various stimulations via up-regulation of GD3 synthase gene (3). Moreover, anti-GD3 monoclonal antibody (mAb)2 induced T cell activation, suggesting that GD3 could mediate growth signals by binding endogenous ligands (4).

In murine T lymphocytes, a number of ganglioside components were present (5, 6) showing changes depending on the stage of development (7) and differentiation of the cells (8). These results indicate that gangliosides play important roles in the immune system. However, many of these studies were done by the addition of exogenous gangliosides (9) or anti-ganglioside antibody to cultured cells (10) or into experimental animals (11). These studies do not address the functions of endogenously generated gangliosides.

We have established mutant mouse lines that completely lacked GM2/GD2 synthase activity and expression of all complex gangliosides including those of asialo-series (12). They showed mild defects in the nervous system, and severe dysfunction in male genital organ (13). In this study, we analyzed the phenotypic and functional changes in the immune system of the complex ganglioside-lacking mice. Most significantly, it was found that mature T cells from the mutant mice respond very weakly to interleukin 2 (IL-2). We elucidated here that the signaling pathway for IL-2/IL-2 receptor (IL-2R) was largely disrupted by the altered ganglioside arrangement on cell surface. This is the first report to study glycolipid functions by the genetic modification of their carbohydrate structures and showed critical roles for endogenous glycolipids in the transduction of proliferation signals introduced by lymphokines.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Flow Cytometry-- For the analysis of IL-2 receptors and gangliosides, spleen cells and thymocytes from 6-8-week-old mice were used. Spleen cells resuspended in phosphate-buffered saline/0.5 mM EDTA/5% fetal calf serum were panned, and then unbound cells were collected and served to flow cytometry. Antibodies used were as follows: PC61 (IL-2Ralpha , 1 µl of ascites), TUm122 (IL-2R beta , 1 µl of ascites), TUGm2 (IL-2Rgamma , 1 µl of ascites) (these three antibodies were kindly provided by Dr. T. Takeshita at Tohoku University), R24 (anti-GD3 provided by Dr. L. J. Old, 0.5 µl of ascites), 220 (anti-GD2, supernatant), 2D4 (anti-GA2 obtained from ATCC, supernatant), 229-6-22 (anti-GA1, supernatant), M2590 (anti-GM3 purchased from Nihon Biotest Research Institute, 5 µg/ml), 370 (anti-GD1b, 0.5 µl of ascites), 549 (anti-GT1b, 0.5 µl of ascites), and 9-22 (anti-GD1a, 0.5 µl of ascites). Additional antibodies used were FITC anti-rat IgG for PC61, TUm122 and TUGm2, FITC anti-mouse IgG for R24 and 220, and FITC anti-mouse IgM for other mouse IgM mAbs. Samples without mAbs were used as negative controls. CD3 expression was analyzed by anti-CD3 mAb145-2C11 and FITC anti-hamster IgG with nonpanned spleen cells. To detect GM1, biotin-labeled choleratoxin B subunit (List Biological Laboratory, Campbell, CA) was used followed by avidin-FITC (EY Laboratories).

T Cell Proliferation Assay-- Spleen cells from mice (6-8 weeks old) were dispersed and washed twice in plain RPMI 1640 medium at 4 °C. They were adjusted at 3.75 × 106/ml in RPMI 1640 containing 10% fetal bovine serum (FBS) and plated into 96-well plates at 100 µl/well. 100 µl of IL-2 was added to make final concentration of 1 unit/ml and cultured. At days 2, 3, 4, and 5 of culture, cells were harvested after incorporation of [3H]thymidine for 18 h (1 µCi/well) by being trapped with a glass filter, and then the filter was counted using a liquid scintillation counter (Aloka, Tokyo). To analyze the response to concanavalin A (ConA) stimulation, ConA was added to the spleen cells prepared as described above at 1~5 µg/ml, and proliferation was examined as performed in IL-2 treatment. Proliferation by stimulation with anti-CD3 antibody was also examined by cultivating spleen cells in 96-well plates coated by mAb145-2C11 at 10 µg/ml, otherwise as done in IL-2 stimulation.

Preparation of Panning Plates-- Anti-mouse IgG (H and L) (Cappel) was coated in 6-cm bacteriological plates (Falcon) at 20 µg/ml in 50 mM Tris-HCl (pH 9.5) for 3 h at room temperature. After washing in saline, the plates were blocked by 0.1% bovine serum albumin in phosphate-buffered saline and then stocked in a freezer.

Immunoprecipitation-- Spleen cells from mice of 6-8 weeks old were cultured in 24-well plates at the density of 1 × 107/ml/well in RPMI 1640 containing 10% FBS. The cells were cultured for 0, 5, 10, and 30 min after addition of IL-2 (1 unit/ml, Takeda Pharmaceutical Co.) (1 Takeda unit = 383 Japan reference unit). The cells were collected at each time point, and then the pellets were lyzed by adding 200 µl of lysis buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM rho -amidinophenyl-methanesulfonyl-fluoride hydrochloride, aprotinin (10 µg/ml), 1% (v/v) Brij96). After centrifugation at 15,000 rpm, the supernatants were precleared with protein A-Sepharose (Amersham Pharmacia Biotech) and then incubated with 10 µl of antibodies (anti-JAK1 (Q-19), anti-JAK3 (C-21), or anti-STAT5b (C-17)) (Santa Cruz Biotechnology Inc.) and then with 20 µl of protein A-Sepharose for 2 h at 4 °C. After washing with lysis buffer three times, the immunoprecipitates were applied to 7.5% gel of SDS-polyacrylamide gel electrophoresis. Proteins were electrically blotted onto polyvinylidene difluoride membranes, and immunoblot was performed by PY-20 (ICN Biomedical Inc.) at 1:2000, anti-JAK1 at 1:4000, anti-JAK3 at 1:4000, and anti-STAT5b at 1:4000 dilution. Second antibodies used were biotinylated anti-mouse IgG for anti-JAK1 and anti-JAK3 and biotinylated anti-rabbit IgG for anti-STAT5b. Signals of antibody binding were detected by ECL detection kit (Amersham Pharmacia Biotech).

Northern Blotting-- Spleen cells from mice (6-8 weeks old) were adjusted at 1 × 107/ml in RPMI 1640 containing 10% FBS and plated in 24-well plates at 2 × 107/well/2 ml. They were cultured for 0, 10, 30, and 60 min in the presence of IL-2 (1 unit/ml). At each time point, cells were collected, and then total RNA was extracted by Trizol® (Life Technologies, Inc.). For Northern blot analysis, total RNA (15 µg/lane) was separated in 1.2% agarose-formaldehyde gel and transferred onto a nylon membrane (GeneScreen Plus, NEN Life Science Products). Prehybridization and hybridization was performed with 32P-radiolabeled cDNA probes synthesized from c-fos or c-myc containing plasmids as described previously (3). Then the membrane was washed and analyzed by a BioImaging Analyzer BAS-2000 (Fuji, Tokyo).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Ganglioside Expression on T Lymphocytes in the Mutant Mice-- GM1, asialo-GM1, and GD1b gangliosides detected in the wild type spleen T cells were completely absent in the mutant spleen cells, as expected from the proposed ganglioside synthetic pathway (Fig. 1, A and B). Instead, GD3 expression was slightly increased in the knock-out mice, probably as a result of precursor accumulation.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 1.   Expected defects of ganglioside synthesis and phenotypic changes in GM2/GD2 synthase gene knock-out mice. A, glycolipids in the box are expected to be deleted in the mutant mice. B, flow cytometric analysis of spleen cells with mAbs. Used antibodies and second antibodies are described under "Experimental Procedures." Solid lines are controls with second antibody alone. C, morphogenesis and cell numbers of spleen and thymus. Total cell numbers were counted and presented as averages of six mice each ± S.D. p values are 0.01 and 0.02 for spleen and thymus, respectively.

Size of Immune Tissues and Numbers of Total Cells and T Cells-- Spleens and thymuses from the mutant mice were smaller than the wild type organs (Fig. 1C). Total cell numbers in the spleens or thymuses of the knock-out mice were significantly reduced as shown in Fig. 1C. The ratios of CD3 positive T cells in the whole spleen cells were almost equivalent between the two groups, i.e. 31.8 ± 1.1% and 31.2 ± 1.6% for the wild type and the mutant mice, respectively.

Proliferation of Spleen Cells-- To compare their proliferation, spleen cells were stimulated with ConA, anti-CD3 antibody, or IL-2. Those from the mutant mice showed clearly decreased incorporation of [3H]thymidine compared with the wild type when stimulated by IL-2 (Fig. 2) but not when treated with ConA or anti-CD3 cross-linking. Because T cell population in the mutant spleen was equivalent to that of the wild type, the results described above indicate that T lymphocytes in the mutant have defects in IL-2/IL-2R-mediated signaling.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 2.   Proliferative reaction of spleen cells to ConA, IL-2 and anti-CD3 antibody. Spleen cells prepared as described under "Experimental Procedures" were stimulated by ConA (2.5 µg/ml), IL-2 (1 unit/ml), or anti-CD3 (10 µg/ml immobilized), and [3H]thymidine uptake was examined. The numbers are average counts ± S.D. ConA stimulation was examined at least three times and showed similar results.

Expression of IL-2 Receptors-- Expression levels of IL-2 receptors were analyzed by flow cytometry. All three components of IL-2 receptor, alpha , beta , and gamma , were equally detected by specific monoclonal antibodies between the wild type and the mutant mice (Fig. 3). After culture with IL-2, their expression patterns were also similar. When they were cultured in the presence of ConA, marked up-regulation of IL-2R alpha  chain was observed in both groups (Fig. 3). Thus, there are no marked differences in the expression levels of IL-2 receptors and in the up-regulation of alpha  chain.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 3.   Expression levels of IL-2 receptors. Expression of three components consisting of IL-2 receptor was analyzed by flow cytometry. Spleen T cells from the wild type (+/+) and the mutant mice (-/-) were analyzed before (left) or after treatment with IL-2 (middle) or with ConA (right) for 3 days as described under "Experimental Procedures."

Activation of JAK-STAT System with IL-2-- To analyze the activation of the JAK/STAT pathway, the phosphorylation patterns of JAK1, JAK3, and STAT5 proteins that are the representative signal molecules responsible for transmission of the IL-2 signal were examined. JAK1 and JAK3 were phosphorylated at 5 min after IL-2 treatment in the wild type mouse T cells, and the activation level was sustained for 10 and 30 min for JAK1 and JAK3, respectively (Fig. 4). On the other hand, JAK1 was scarcely phospholylated, and JAK3 phosphorylation detected at 5 min quickly returned to the basal line in the mutant mice. STAT5 was also phosphorylated at 5 min after IL-2 stimulation and kept the activated form even after 30 min in the wild type. In contrast, the mutant spleen cells showed delayed response and already declined at 30 min after IL-2 treatment (Fig. 4C).


View larger version (72K):
[in this window]
[in a new window]
 
Fig. 4.   JAK/STAT activation after IL-2 stimulation of spleen T cells. Spleen cells were cultured in the presence of IL-2 for the times indicated and then served to immunoprecipitation (IP) and Western immunoblots as described under "Experimental Procedures" and as indicated in the figure. Immunoprecipitation was performed by anti-JAK1 (A), anti-JAK3 (B), or anti-STAT5b (C) and then blotted by anti-phosphotyrosine mAb (PY20) or individual antibodies used for immunoprecipitation as controls.

c-myc and c-fos Gene Expression during IL-2 Stimulation-- c-fos/c-jun, c-myc, or bcl2 has been reported to be involved in the cell proliferation by IL-2 (14). We analyzed the regulation of c-fos and c-myc gene transcription when stimulated with IL-2. mRNA of c-fos in the wild type mice was readily detected by Northern blotting 10 min after IL-2 stimulation and then gradually decreased. In the mutant mouse, c-fos mRNA levels reached the plateau at 30 min and soon fell (Fig. 5A). On the other hand, c-myc mRNA levels exhibited very similar patterns in the mutant and wild type mice.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 5.   c-fos and c-myc expression during IL-2 stimulation of spleen cells. Spleen cells were cultured in the presence of IL-2 for the times indicated and then served to Northern blotting as described under "Experimental Procedures." The intensity of bands were measured by Bas2000 imaging analyzer (Fuji, Tokyo), and both graphs assign an intensity of 1 to time 0 of the wild type and express intensity at subsequent time points relative to time 0.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Ganglioside GM2/GD2 synthase gene knock-out mice showed defects in ganglioside expression on T cells in accord with the proposed pathway of ganglioside synthesis (15). The comparative study of the immune system using these mutant mice, as well as the wild type mice, is expected to unambiguously elucidate the actual roles of gangliosides in vivo. In fact, results obtained here clearly showed important roles of gangliosides in the regulation of IL-2/IL-2R-mediated signals in a straightforward manner.

In many studies, the roles of glycolipids in the immune system have been analyzed by observing the effects of exogenous gangliosides, and they exhibited suppressive effects on T cell functions such as CD4 internalization (9) and reduced response to mitogens or allogeneic antigens (16). Actually, gangliosides were reported to bind to IL-2 (17) and thereby inhibit T cell proliferation (18). These immunosuppressive effects of gangliosides have been considered to explain immunosuppression in cancer patients (19). However, results obtained in these experiments do not seem likely to reflect the real effects of endogenously generated gangliosides.

Compartmentalization through protein-protein or protein-lipid interactions has now been recognized as a fundamental mechanism for efficient and organized cell signaling (20, 21). Some membrane components are apparently organized into glycolipid-enriched membrane domains or detergent-insoluble glycolipid-enriched domains (22) known as rafts. These rafts are enriched in sphingolipids, cholesterol, glycosylphosphatidyl-inositol-anchored proteins (23), and a variety of signaling molecules. Recently, dynamic T cell receptor recruitment to such a microdomain upon T cell activation has been reported in a T cell line (24, 25) and in thymocytes (26). These data suggest that gangliosides expressed on T cells associate with receptors and signaling molecules to transduce the IL-2 signals at such a microdomain, although it is yet unclear that IL-2 receptors are enriched in glycolipid-enriched membrane domains.

Defects in the IL-2 signal transduction found in the mutant mice T cells should take place due to lack of GM1/GD1b/GA1 and may be due to serious structural defects of IL-2 receptors. In particular, the configuration of beta  and gamma  chains may be affected because it has been reported that JAK1 and JAK3 are differentially associated with IL-2Rbeta and IL-2Rgamma , respectively (27). Among many signaling molecules, JAK3 is reported to mainly act in cell proliferation and to activate STAT5 (28) and induce c-fos expression (29). Reduced activation of JAK3 and JAK1 followed by reduced activation of STAT5 and reduced c-fos induction upon IL-2 stimulation may explain the suppressed proliferation of the mutant T cells. The fact that all mutant mice deficient for IL-2/IL-2Rs, except for those deficient in IL-2Rgamma , show deregulated T cell activation and autoimmune diseases (30) suggests that the defects in the immune system of our mutant mice might come mainly from attenuation in the gamma  chain-mediated signal.

Results presented in this report demonstrate a possibility that cell surface gangliosides regulate the proliferation signals by modulating the growth factor receptors. These findings will provide insights into the roles of gangliosides in the proliferation of activated T lymphocytes (3) and T cell leukemia cells (31, 32) and also may provide clues to developing new therapeutic approaches for malignant lymphoid tumors.

    ACKNOWLEDGEMENTS

We thank Dr. K. O. Lloyd at Memorial Sloan-Kettering Cancer Center for critically reading the manuscript and Dr. T. Tabeshita for providing anti-IL-2R mAbs. We also thank the members of the Laboratory Animal Center for Biomedical Research, Nagasaki University School of Medicine for the care of the mice.

    FOOTNOTES

* This work was supported by a Grant-in-Aid for Scientific Research of Priority Areas 10178105 and by a grant from the Core of Excellence from the Ministry of Education, Science, Sports, and Culture of Japan.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§§ Present address: Dept. of Neuroscience, Johns Hopkins University, Baltimore, MD 21205.

|| To whom correspondence should be addressed: Dept. of Biochemistry II, Nagoya University School of Medicine, 65 Tsurumai, Showa-ku, Nagoya 466-0065 Japan. Tel.: 81-52-744-2070; Fax: 81-52-744-2069; E-mail: koichi{at}med.nagoya-u.ac.jp.

1 Ganglioside nomenclature is based on that of Svennerholm (33).

    ABBREVIATIONS

The abbreviations used are: mAb, monoclonal antibody; FBS, fetal bovine serum; IL-2, interleukin 2; IL-2R, IL-2 receptor; FITC, fluorescein isothiocyanate, ConA, concanavalin A.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Ledeen, R. W., Wu, G., Lu, Z. H., Kozireski-Chuback, D., and Fang, Y. (1998) Ann. N. Y. Acad. Sci. 845, 161-175[Abstract/Free Full Text]
  2. Hakomori, S. (1990) J. Biol. Chem. 265, 18713-18716[Abstract/Free Full Text]
  3. Yamashiro, S., Okada, M., Haraguchi, M., Furukawa, K., Lloyd, K. O., Shiku, H., and Furukawa, K. (1995) Glycoconj. J. 12, 894-900[Medline] [Order article via Infotrieve]
  4. Welte, K., Miller, G., Chapman, P. B., Yuasa, H., Natoli, E., and Houghton, A. N. (1987) J. Immunol. 139, 1763-1771[Abstract/Free Full Text]
  5. Schwarting, G. A., and Gajewski, A. (1983) J. Biol. Chem. 258, 5893-5898[Abstract/Free Full Text]
  6. Nakamura, K., Hashimoto, Y., Yamakawa, T., and Suzuki, A. (1988) J. Biochem. (Tokyo) 103, 201-208[Abstract]
  7. Suttles, J., Schwarting, G. A., Hougland, M. W., and Stout, R. D. (1987) J. Immunol. 138, 364-372[Abstract/Free Full Text]
  8. Stein-Douglas, K., Schwarting, G. A., Naiki, M., and Marcus, D. M. (1976) J. Exp. Med. 143, 822-832[Abstract]
  9. Offner, H., Thieme, T., and Vandenbark, A. A. (1987) J. Immunol. 139, 3295-3305[Abstract/Free Full Text]
  10. Ting, C. C., Bluestone, J. A., Hargrove, M. E., and Loh, N. N. (1986) J. Immunol. 137, 2100-2106[Abstract/Free Full Text]
  11. Barlozzari, T., Reynolds, C. W., and Herberman, R. B. (1983) J. Immunol. 131, 1024-1027[Abstract/Free Full Text]
  12. Takamiya, K., Yamamoto, A., Furukawa, K., Yamashiro, S., Masashi, S., Okada, M., Fukumoto, S., Haraguchi, M., Takeda, N., Fujimura, K., Sakae, M., Kishikawa, M., Shiku, H., Furukawa, K., and Aizawa, S. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 10662-10667[Abstract/Free Full Text]
  13. Takamiya, K., Yamamoto, A., Furukawa, K., Zhao, J., Fukumoto, S., Yamashiro, S., Okada, M., Haraguchi, M., Shin, M., Kishikawa, M., Shiku, H., Aizawa, S., and Furukawa, K. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 12147-12152[Abstract/Free Full Text]
  14. Miyazaki, T., Liu, Z.-J., Kawahara, A., Minami, Y., Yamada, K., Tsujimoto, Y., Barsoumian, E. L., Perlmutter, R. M., and Taniguchi, T. (1995) Cell 81, 223-231[Medline] [Order article via Infotrieve]
  15. Pohlentz, G., Klein, D., Schwarzmann, G., Schmitz, D., and Sandhoff, K. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 4638-4643[Abstract]
  16. Whisler, R. L., and Yates, A. J. (1980) J. Immunol. 125, 2106-2111[Abstract/Free Full Text]
  17. Parker, J., Caldini, G., Krishnamurti, C., Ahrens, P. B., and Ankel, H. (1984) FEBS Lett. 170, 391-395[CrossRef][Medline] [Order article via Infotrieve]
  18. Robb, R. J. (1986) J. Immunol. 136, 971-976[Abstract/Free Full Text]
  19. Floutsis, G., Ulsh, L., and Ladisch, S. (1989) Int. J. Cancer 43, 6-9[Medline] [Order article via Infotrieve]
  20. Liu, P., Ying, Y., and Anderson, R. G. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 13666-13670[Abstract/Free Full Text]
  21. Pawson, T., and Scott, J. D. (1997) Science 278, 2075-2080[Abstract/Free Full Text]
  22. Harder, T., and Simons, K. (1997) Curr. Opin. Cell Biol. 9, 534-542[CrossRef][Medline] [Order article via Infotrieve]
  23. Brown, D. A., and Rose, J. K. (1992) Cell 68, 533-544[Medline] [Order article via Infotrieve]
  24. Xavier, R., Brennan, T., Li, Q., McCormack, C., and Seed, B. (1998) Immunity 8, 723-732[Medline] [Order article via Infotrieve]
  25. Zhang, W., Trible, R. P., and Samelson, L. E. (1998) Immunity 9, 239-246[Medline] [Order article via Infotrieve]
  26. Montixi, C., Langlet, C., Bernard, A.-M., Thimonier, J., Dubois, C., Wurbel, M.-A., Chauvin, J.-P., Pierres, M., and He, H.-T. (1998) EMBO J. 17, 5334-5348[Abstract/Free Full Text]
  27. Miyazaki, T., Kawahara, A., Fujii, H., Nakagawa, Y., Minami, Y., Liu, Z. J., Oishi, I., Silvennoinen, O., Witthuhn, B. A., Ihle, J. N., and Taniguchi, T. (1994) Science 266, 1045-1047[Medline] [Order article via Infotrieve]
  28. Fujii, H., Nakagawa, Y., Schindler, U., Kawahara, A., Mori, H., Goulleux, F., Groner, B., Ihle, N. J., Minami, Y., Miyazaki, T., and Taniguchi, T. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 5482-5486[Abstract]
  29. Kawahara, A., Minami, Y., Miyazaki, T., Ihle, N. J., and Taniguchi, T. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8724-8728[Abstract]
  30. Theze, J., Alzari, P. M., and Bertoglio, J. (1996) Immunol. Today 17, 481-486[CrossRef][Medline] [Order article via Infotrieve]
  31. Furukawa, K., Akagi, T., Nagata, Y., Yamada, Y., Shimotohno, K., Cheung, N.-K. V., Shiku, H., and Furukawa, K. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 1972-1976[Abstract]
  32. Okada, M., Furukawa, K., Yamashiro, S., Yamada, Y., Haraguchi, M., Horibe, K., Kato, K., Tsuji, Y., Shiku, H., and Furukawa, K. (1996) Cancer Res. 56, 2844-2848[Abstract]
  33. Svennerholm, L. (1963) J. Neurochem. 10, 613-623[Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.